Evidence map›Paper›PMID 38769505›Full record

ArticleBMC bioinformatics2024

PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning.

Zhenyu Wei, Chengkui Zhao, Min Zhang, Jiayu Xu, Nan Xu, Shiwei Wu, Xiaohui Xin, Lei Yu, Weixing Feng

Abstract read
In one paragraph

Article in BMC bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhenyu WeiIntelligent Systems Science and Engineering College, Harbin Engineering University, Liaoyuan Street, Harbin, 150006, Heilongjiang Province, People's Republic of China. 952376687@hrbeu.edu.cn.
Chengkui ZhaoIntelligent Systems Science and Engineering College, Harbin Engineering University, Liaoyuan Street, Harbin, 150006, Heilongjiang Province, People's Republic of China.
Min ZhangIntelligent Systems Science and Engineering College, Harbin Engineering University, Liaoyuan Street, Harbin, 150006, Heilongjiang Province, People's Republic of China.
Jiayu XuIntelligent Systems Science and Engineering College, Harbin Engineering University, Liaoyuan Street, Harbin, 150006, Heilongjiang Province, People's Republic of China.
Nan XuSchool of Chemical and Molecular Engineering, East China Normal University, Zhongshan North Street, Shanghai, 200000, People's Republic of China.
Shiwei WuIntelligent Systems Science and Engineering College, Harbin Engineering University, Liaoyuan Street, Harbin, 150006, Heilongjiang Province, People's Republic of China.
Xiaohui XinIntelligent Systems Science and Engineering College, Harbin Engineering University, Liaoyuan Street, Harbin, 150006, Heilongjiang Province, People's Republic of China.
Lei YuSchool of Chemical and Molecular Engineering, East China Normal University, Zhongshan North Street, Shanghai, 200000, People's Republic of China. ylyh188@163.com.
Weixing FengIntelligent Systems Science and Engineering College, Harbin Engineering University, Liaoyuan Street, Harbin, 150006, Heilongjiang Province, People's Republic of China. Fengweixing@hrbeu.edu.cn.

Funding

National Natural Science Foundation of China 62172121National Natural Science Foundation of China 82073800Natural Science Foundation of Heilongjiang Province of China LH2022F012
6 · The paper itself

Abstract

backgroundCAR-T cell therapy represents a novel approach for the treatment of hematologic malignancies and solid tumors. However, its implementation is accompanied by the emergence of potentially life-threatening adverse events known as cytokine release syndrome (CRS). Given the escalating number of patients undergoing CAR-T therapy, there is an urgent need to develop predictive models for severe CRS occurrence to prevent it in advance. Currently, all existing models are based on decision trees whose accuracy is far from meeting our expectations, and there is a lack of deep learning models to predict the occurrence of severe CRS more accurately.

resultsWe propose PrCRS, a deep learning prediction model based on U-net and Transformer. Given the limited data available for CAR-T patients, we employ transfer learning using data from COVID-19 patients. The comprehensive evaluation demonstrates the superiority of the PrCRS model over other state-of-the-art methods for predicting CRS occurrence. We propose six models to forecast the probability of severe CRS for patients with one, two, and three days in advance. Additionally, we present a strategy to convert the model's output into actual probabilities of severe CRS and provide corresponding predictions.

conclusionsBased on our findings, PrCRS effectively predicts both the likelihood and timing of severe CRS in patients, thereby facilitating expedited and precise patient assessment, thus making a significant contribution to medical research. There is little research on applying deep learning algorithms to predict CRS, and our study fills this gap. This makes our research more novel and significant. Our code is publicly available at https://github.com/wzy38828201/PrCRS . The website of our prediction platform is: http://prediction.unicar-therapy.com/index-en.html .

Indexed as

COVID-19Cytokine Release SyndromeDeep LearningImmunotherapy, AdoptiveHumansNeoplasmsSARS-CoV-2CAR-T immunotherapyCRSDeep learningPlatformTransfer learning

Identifiers

PMID38769505
PMCPMC11106915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.